Anti inhibitor Coagulant Complex

Anti inhibitor Coagulant Complex Brand Names

FEIBA | FEIBA NF | Feiba NF Immuno | FEIBA VH Immuno

What is Anti inhibitor Coagulant Complex

Anti- inhibitor coagulant complex (AICC) is derived from human plasma.

Anti inhibitor coagulant complex is similar to prothrombin complex concentrates (PCCs or factor IX complexes), but AICC has undergone in vitro activation resulting in an increased amount of activated and precursor vitamin K-dependent clotting factors (factors II, VII, IX, and X).

Anti inhibitor coagulant complex is used as coagulation factor bypass therapy in patients with hemophilia with inhibitors or in patients with acquired inhibitors to other clotting factors.

In patients with high inhibitor titers (more than 10 Bethesda Units) or who rapidly develop inhibitors following exposure to factor products (high responders), AICC provides activated clotting factors and controls bleeding in about 80% to 90% of patients with 1 or 2 doses.

FEIBA products contain factors II, IX, and X, which are mainly inactivated, and factor VII, which is mainly activated.

FEIBA contains only trace amounts of factors of the kinin generating system and no heparin.

The activity of FEIBA is expressed in arbitrary units; 1 unit of activity is defined as the amount of FEIBA that shortens the aPTT of high titer factor VIII inhibitor reference plasma to 50% of the blank value.

These products undergo processes that are designed to reduce the risk of infectious contamination.

Indications

1. bleeding prophylaxis
2. dabigatran reversal
3. factor VII deficiency
4. hemarthrosis
5. hemophilia A
6. hemophilia B
7. hemorrhage
8. rivaroxaban reversal
9. surgical bleeding
10. von Willebrand’s disease

For the control and prevention of bleeding episodes (i.e., hemorrhage, hemarthrosis), perioperative management (surgical bleeding), and routine bleeding prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or hemophilia B with inhibitors or patients with acquired inhibitors to other factors including patients with factor VII deficiency† or von Willebrand’s disease

Side Effects

1. anaphylactoid reactions
2. anemia
3. angioedema
4. bronchospasm
5. chest pain (unspecified)
6. chills
7. diarrhea
8. disseminated intravascular coagulation (DIC)
9. dizziness
10. drowsiness
11. dysgeusia
12. dyspnea
13. fever
14. flushing
15. hot flashes
16. hypertension
17. hypoesthesia
18. hypotension
19. infection
20. infusion-related reactions
21. injection site reaction
22. malaise
23. myocardial infarction
24. nausea
25. pruritus
26. pulmonary embolism
27. sinus tachycardia
28. stroke
29. thromboembolism
30. urticaria
31. vomiting
32. wheezing

Monitoring Parameters

• activated partial thromboplastin time (APTT)
• clotting inhibitor titers

Contraindications

• breast-feeding
• children
• disseminated intravascular coagulation (DIC)
• myocardial infarction
• pregnancy
• thrombocytopenia
• thromboembolism
• viral infection

Interactions

• Aminocaproic Acid
• Emicizumab
• Tranexamic Acid